Stock Groups

AstraZeneca chairman to retire in 2023, search for successor underway -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: Britain’s Prince Charles and AstraZeneca Chairman Leif Johansson smile during a visit at the AstraZeneca global R&D facility at the Cambridge Biomedical Campus in Cambridge, Britain November 23, 2021. Chris Jackson/Pool via REUTERS

(Reuters) -AstraZeneca announced Tuesday that its chairman non-executive Leif Johansson will step down next year after the Anglo-Swedish drugmaker has held an annual general meeting. He had served in this role for 11 years.

At the time Pascal Soriot, Chief Executive Officer, took over, Soriot, a 70-year old Swedish businessman, was elected chairman. According to Soriot, succession planning has already started for Johansson in a interview with Financial Times last May.

On Tuesday, the company stated that it was continuing to search for a replacement chair.

AstraZeneca (NASDAQ 🙂 asked Johansson in 2012 to keep his position as overseer of its recently-completed acquisition for $39B Alexion, which is a rare disease medicine maker.

AstraZeneca stated in a statement that “The Board believes it is in the shareholders’ best interests for Mr Johansson seek re-election in April 2022, and continue as Chair for one more year.”

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this website’s data including quotes and charts. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]